Boehringer Ingelheim is introducing a program to cap out-of-pocket costs at $35 a month for their inhalers used to treat asthma and chronic obstructive pulmonary disease. The initiative, starting on June 1, aims to assist Americans with commercial health insurance, as well as those without insurance who pay cash for their inhalers. This move is seen as a way to help vulnerable patients in response to complaints about the high cost of prescription drugs. The company’s U.S. operations head, Jean-Michel Boers, believes this program will provide a fair and predictable experience for patients, especially those who are underinsured.
Source link
Boehringer Ingelheim sets $35 cap on asthma inhaler out-of-pocket costs
